Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Martin, Caren McHenry
2010.
Off-Label Use of Medications: Innovative Prescribing or Risky Business?.
The Consultant Pharmacist,
Vol. 25,
Issue. 12,
p.
806.
McCullough, Laurence B.
Chervenak, Frank A.
Brent, Robert L.
and
Hippen, Benjamin
2010.
A Case Study in Unethical Transgressive Bioethics: “Letter of Concern from Bioethicists” About the Prenatal Administration of Dexamethasone.
The American Journal of Bioethics,
Vol. 10,
Issue. 9,
p.
35.
Frader, Joel
2010.
Speaking of Accuracy.
The American Journal of Bioethics,
Vol. 10,
Issue. 9,
p.
52.
Malek, Antoine
and
Mattison, Donald R
2010.
Drug development for use during pregnancy: impact of the placenta.
Expert Review of Obstetrics & Gynecology,
Vol. 5,
Issue. 4,
p.
437.
Hyun, Insoo
2010.
Allowing Innovative Stem Cell-Based Therapies outside of Clinical Trials: Ethical and Policy Challenges.
Journal of Law, Medicine & Ethics,
Vol. 38,
Issue. 2,
p.
277.
Minghetti, Paola
Palmieri, Iolanda
and
Selmin, Francesca
2010.
When authorized medicinal products are not available: possible alternatives to meet legitimate expectations of patients.
Journal of Pharmaceutical Health Services Research,
Vol. 1,
Issue. 3,
p.
107.
Scott Morton, Fiona
and
Kyle, Margaret
2011.
Vol. 2,
Issue. ,
p.
763.
Van Allen, Eliezer M.
Miyake, Todd
Gunn, Nathan
Behler, Caroline M.
and
Kohlwes, Jeff
2011.
Off-Label Use of Rituximab in a Multipayer Insurance System.
Journal of Oncology Practice,
Vol. 7,
Issue. 2,
p.
76.
Guidi, Benedetta
Nocco, Luca
Rizzi, Marco
and
Walbaum Robinson, Isabel A.
2011.
Opinio Juris in Comparatione Vol. 1/2011.
SSRN Electronic Journal,
Brody, Howard
and
Light, Donald W.
2011.
The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health.
American Journal of Public Health,
Vol. 101,
Issue. 3,
p.
399.
Berland-Benhaïm, C
Giocanti, D
Bartoli, C
Sastre, C
Leonetti, G
and
Pelissier-Alicot, Al
2011.
Medication misuse and abuse: duties and responsibilities of dispensing pharmacists.
Medicine, Science and the Law,
Vol. 51,
Issue. 1,
p.
49.
Morris, J
2012.
The Use of Observational Health-Care Data to Identify and Report on Off-Label Use of Biopharmaceutical Products.
Clinical Pharmacology & Therapeutics,
Vol. 91,
Issue. 5,
p.
937.
Lowenthal, Justin
Hull, Sara Chandros
and
Pearson, Steven D.
2012.
The Ethics of Early Evidence — Preparing for a Possible Breakthrough in Alzheimer's Disease.
New England Journal of Medicine,
Vol. 367,
Issue. 6,
p.
488.
Ruble, James
2012.
Off-Label Prescribing of Medications for Pain: Maintaining Optimal Care at an Intersection of Law, Public Policy, and Ethics.
Journal of Pain & Palliative Care Pharmacotherapy,
Vol. 26,
Issue. 2,
p.
146.
Dreger, Alice
Feder, Ellen K.
and
Tamar-Mattis, Anne
2012.
Prenatal Dexamethasone for Congenital Adrenal Hyperplasia.
Journal of Bioethical Inquiry,
Vol. 9,
Issue. 3,
p.
277.
Dove, Edward S.
Özdemir, Vural
and
Joly, Yann
2012.
Harnessing Omics Sciences, Population Databases, and Open Innovation Models for Theranostics‐Guided Drug Discovery and Development.
Drug Development Research,
Vol. 73,
Issue. 7,
p.
439.
Wittich, Christopher M.
Burkle, Christopher M.
and
Lanier, William L.
2012.
Ten Common Questions (and Their Answers) About Off-label Drug Use.
Mayo Clinic Proceedings,
Vol. 87,
Issue. 10,
p.
982.
Cole, Lindsay W.
Kesselheim, Jennifer C.
and
Kesselheim, Aaron S.
2012.
Ethical Issues in New Drug Prescribing.
Journal of Bioethical Inquiry,
Vol. 9,
Issue. 1,
p.
77.
Devane, C. Lindsay
2012.
Pharmacotherapy of Child and Adolescent Psychiatric Disorders.
p.
25.
Mellor, J. D.
Van Koeverden, P.
Yip, S. W. K.
Thakerar, A.
Kirsa, S. W.
and
Michael, M.
2012.
Access to anticancer drugs: many evidence‐based treatments are off‐label and unfunded by the Pharmaceutical Benefits Scheme.
Internal Medicine Journal,
Vol. 42,
Issue. 11,
p.
1224.